Hormone titers are affected by interplay between secretion and inactiv
ation processes. While secretion is a focal process, inactivation mech
anisms are often complex and poorly understood. In the present study,
inactivation of cardiovascular regulatory hormones was examined from a
physiological perspective by analyzing the half-time (t(1/2)) for rec
overy of dorsal and ventral aortic and central venous pressure, cardia
c output, heart rate, and systemic and branchial vascular resistance f
ollowing infusion or injection of hormones into conscious rainbow trou
t, Oncorhynchus mykiss. When possible, these were compared to recovery
t(1/2), of isolated vessel rings in vitro. The t(1/2) for epinephrine
or norepinephrine recovery in vivo was 3-4 min, approximately twice a
s long as recovery t(1/2) for isolated celiacomesenteric and epibranch
ial artery rings in vitro. Thus, the rate-limiting step in vascular re
laxation is the concentration of circulating catecholamine concentrati
ons, and not metabolic or mechanical events within the vascular wall.
The in vivo recovery t(1/2) following angiotensin II (ANG II) infusion
was 6-7 min, nearly twice that of catecholamines, but also greater th
an the t(1/2) following bolus ANG II injection, inhibition of angioten
sin converting enzyme with captopril or injection of trout bradykinin.
Arginine vasotocin (AVT) recovery t(1/2) in vivo, was considerably lo
nger (20-30 min) than either catecholamine or ANG II t(1/2) and longer
than AVT recovery t(1/2) of isolated vessels in vitro (5-6 min). The
inactivation kinetics of catecholamines are consistent with circulator
y convection-limited processes and do not appear to be limited by eith
er tissue uptake or enzymatic degradation. This is probably the fastes
t type of 'on-off' endocrine regulation in fish. Inactivation of ANG I
I and bradykinin are also convection limited, but ANG II metabolism ma
y become saturated with high doses of exogenous ANG II. AVT inactivati
on is not convection limited and may compensate for a quantitatively l
ower capacity of the pituitary for peptide secretion, or less emphasis
on AVT as an on/off effector of vascular resistance. (C) 1997 Wiley-L
iss, Inc.